BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37041591)

  • 21. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.
    Jiang B; Wu X; Li XN; Yang X; Zhou Y; Yan H; Wei AH; Yan W
    Cell Immunol; 2014 Jul; 290(1):10-20. PubMed ID: 24859012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
    Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
    Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study on the construction and expression of the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein].
    Jiang W; Xiong D; Liu F; Guo H; Su Y; Lü J; Yang C
    Sheng Wu Gong Cheng Xue Bao; 2008 Mar; 24(3):376-80. PubMed ID: 18589811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded CD56
    Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
    Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.
    Xiao H; Huang B; Yuan Y; Li D; Han LF; Liu Y; Gong W; Wu FH; Zhang GM; Feng ZH
    Clin Cancer Res; 2007 Mar; 13(6):1823-30. PubMed ID: 17325342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
    Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
    PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
    Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
    Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB.
    Loo DT; Chalupny NJ; Bajorath J; Shuford WW; Mittler RS; Aruffo A
    J Biol Chem; 1997 Mar; 272(10):6448-56. PubMed ID: 9045669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells.
    Zhao Q; Pang J; Yan F; Jiang Y; Cui D; Liu J; Jing L; Li Y; Liu Z; Tao L; Zhao X; Diao A
    Protein Expr Purif; 2021 Feb; 178():105783. PubMed ID: 33122138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.
    Fellermeier S; Beha N; Meyer JE; Ring S; Bader S; Kontermann RE; Müller D
    Oncoimmunology; 2016; 5(11):e1238540. PubMed ID: 27999756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
    Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
    Front Immunol; 2022; 13():841859. PubMed ID: 35281028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.
    Mbanwi AN; Lin GHY; Wang KC; Watts TH
    J Immunol Methods; 2017 Nov; 450():81-89. PubMed ID: 28789924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.